Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
thrombocytopenic purpura
MeSH D011696 - thrombocytopenic purpura
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D011693:
Purpura
5 Companies
1 Drug
$
Success rate
D057049:
Thrombotic microangiopathies
0 Companies
0 Drugs
Success rate
D007154:
Immune system diseases
2 Companies
2 Drugs
$
Success rate
D011696:
Thrombocytopenic purpura
1 Company
1 Drug
$
Success rate
D011697:
Thrombotic thrombocytopenic purpura
1 Company
1 Drug
$
Success rate
D016553:
Thrombocytopenic purpura idiopathic
100 Companies
15 Drugs
$
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
100
%
1/1
Phase 2
27
%
3/11
Phase 3
25
%
1/4
Approved:
1
Overall Success rate:
7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Merck & Co
Interferon alfa-2b
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use